LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

LLY

1,059.82

+3.15%↑

JNJ

214.04

+1.23%↑

ABBV

226.73

+1.47%↑

UNH

340.92

-0.14%↓

AZN

91.05

+1.4%↑

Начало・Списък с акции・Prothena Corp PLC

Prothena Corp PLC

Отворен

СекторЗдравеопазване

10 -3.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.91

Максимум

10.46

Ключови измерители
By Trading Economics
Приходи	89M -37M
Продажби	-2M 2.4M
Марж на печалбата	-1,513.085
Служители	163
EBITDA	16M -36M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+100.77% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	10M 578M
Предишно отваряне	13.29
Предишно затваряне	10

Настроения в новините

By Acuity

34%

66%

85 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 7.35 Подкрепа & съпротива

Prothena Corp PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.12.2025 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13.12.2025 г., 00:04 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14.12.2025 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Take Full Control of US$101M Copper Miner Alta

14.12.2025 г., 22:02 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14.12.2025 г., 22:01 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14.12.2025 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14.12.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Fortescue to Acquire Remaining 64% of Alta Copper

14.12.2025 г., 17:00 ч. UTC

Печалби

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14.12.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13.12.2025 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 08:00 ч. UTC

Придобивния, сливания и поглъщания

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13.12.2025 г., 07:00 ч. UTC

Придобивния, сливания и поглъщания

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13.12.2025 г., 00:24 ч. UTC

Придобивния, сливания и поглъщания

Want a Piece Of SpaceX? -- Barrons.com

12.12.2025 г., 23:49 ч. UTC

Придобивния, сливания и поглъщания

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12.12.2025 г., 22:52 ч. UTC

Пазарно говорене

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12.12.2025 г., 22:32 ч. UTC

Печалби

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.12.2025 г., 20:45 ч. UTC

Печалби

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12.12.2025 г., 20:41 ч. UTC

Пазарно говорене

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12.12.2025 г., 20:20 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12.12.2025 г., 19:23 ч. UTC

Печалби

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12.12.2025 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12.12.2025 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12.12.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12.12.2025 г., 17:49 ч. UTC

Печалби

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12.12.2025 г., 17:34 ч. UTC

Придобивния, сливания и поглъщания

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение с други в отрасъла

Ценова промяна

Prothena Corp PLC Прогноза

Ценова цел

By TipRanks

100.77% нагоре

12-месечна прогноза

Среден 20.8 USD 100.77%

Висок 36 USD

Нисък 8 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Prothena Corp PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Prothena Corp PLC през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 7.35Подкрепа & съпротива

All events are bearish.

Настроение

By Acuity

85 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.